Citadel Advisors’s Cogentix Medical, Inc. CGNT Stock Holding History

Citadel Advisors’s Portfolio CGNT Stock Details CGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-21,227	Closed	-$82K	–	9665
2018 Q1	$82K	Buy	+21,227	New	+$66.4K	﹤0.01%	7783
2017 Q4	–	Sell	-11,197	Closed	-$29K	–	8758
2017 Q3	$29K	Buy	+11,197	New	+$24.5K	﹤0.01%	7299
2017 Q2	–	Sell	-10,200	Closed	-$18K	–	8460
2017 Q1	$18K	Buy	+10,200	New	+$20.2K	﹤0.01%	7280
2016 Q1	–	Sell	-14,184	Closed	-$18K	–	8730
2015 Q4	$18K	Sell	14,184 -1,633	-10%	-$2.23K	﹤0.01%	8021
2015 Q3	$20K	Buy	15,817 +5,703	+56%	+$8.74K	﹤0.01%	8162
2015 Q2	$16K	Buy	+10,114	New	+$16.6K	﹤0.01%	8270

Citadel Advisors's CGNT Position: Q2 2018 in Review

Citadel Advisors sold out of Cogentix Medical, Inc. (CGNT) in Q2 2018, closing a stake of 21,227 shares — an estimated $82K sold.

Citadel Advisors first reported a position in CGNT in Q2 2015 and held it in 6 quarters. The position peaked at $82K in Q1 2018. 0 funds tracked by Wall St. Rank hold CGNT as of Q2 2018.

Citadel Advisors reported no remaining Cogentix Medical, Inc. position as of Q2 2018 after selling out during the quarter.
Citadel Advisors sold 21,227 Cogentix Medical, Inc. shares in Q2 2018, an estimated $82K.
Citadel Advisors first reported a position in Cogentix Medical, Inc. in Q2 2015 and held it in 6 quarters.
Citadel Advisors's Cogentix Medical, Inc. position peaked at $82K in Q1 2018.
0 funds tracked by Wall St. Rank held Cogentix Medical, Inc. as of Q2 2018.

Based on Citadel Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.